These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

707 related articles for article (PubMed ID: 9342501)

  • 1. Clinical pharmacokinetics of irinotecan.
    Chabot GG
    Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Irinotecan pharmacokinetics].
    Chabot GG; Robert J; Lokiec F; Canal P
    Bull Cancer; 1998 Dec; Spec No():11-20. PubMed ID: 9932079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
    Chabot GG; Abigerges D; Catimel G; Culine S; de Forni M; Extra JM; Mahjoubi M; Hérait P; Armand JP; Bugat R
    Ann Oncol; 1995 Feb; 6(2):141-51. PubMed ID: 7786822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
    Catimel G; Chabot GG; Guastalla JP; Dumortier A; Cote C; Engel C; Gouyette A; Mathieu-Boué A; Mahjoubi M; Clavel M
    Ann Oncol; 1995 Feb; 6(2):133-40. PubMed ID: 7786821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.
    Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
    J Clin Oncol; 2002 Aug; 20(15):3293-301. PubMed ID: 12149304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.
    Crews KR; Stewart CF; Jones-Wallace D; Thompson SJ; Houghton PJ; Heideman RL; Fouladi M; Bowers DC; Chintagumpala MM; Gajjar A
    Clin Cancer Res; 2002 Jul; 8(7):2202-9. PubMed ID: 12114421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
    J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
    Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
    Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials.
    Rivory LP; Haaz MC; Canal P; Lokiec F; Armand JP; Robert J
    Clin Cancer Res; 1997 Aug; 3(8):1261-6. PubMed ID: 9815808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats.
    Itoh T; Itagaki S; Sasaki K; Hirano T; Takemoto I; Iseki K
    J Pharm Pharmacol; 2004 Jun; 56(6):809-12. PubMed ID: 15231047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38.
    Dodds HM; Haaz MC; Riou JF; Robert J; Rivory LP
    J Pharmacol Exp Ther; 1998 Jul; 286(1):578-83. PubMed ID: 9655905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
    Rothenberg ML; Kuhn JG; Schaaf LJ; Rodriguez GI; Eckhardt SG; Villalona-Calero MA; Rinaldi DA; Hammond LA; Hodges S; Sharma A; Elfring GL; Petit RG; Locker PK; Miller LL; von Hoff DD
    Ann Oncol; 2001 Nov; 12(11):1631-41. PubMed ID: 11822765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin.
    de Jonge MJ; Verweij J; de Bruijn P; Brouwer E; Mathijssen RH; van Alphen RJ; de Boer-Dennert MM; Vernillet L; Jacques C; Sparreboom A
    J Clin Oncol; 2000 Jan; 18(1):195-203. PubMed ID: 10623710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan.
    Ma MK; Zamboni WC; Radomski KM; Furman WL; Santana VM; Houghton PJ; Hanna SK; Smith AK; Stewart CF
    Clin Cancer Res; 2000 Mar; 6(3):813-9. PubMed ID: 10741701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.
    Gupta E; Mick R; Ramirez J; Wang X; Lestingi TM; Vokes EE; Ratain MJ
    J Clin Oncol; 1997 Apr; 15(4):1502-10. PubMed ID: 9193346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies.
    Escoriaza J; Aldaz A; Castellanos C; Calvo E; Giráldez J
    J Chromatogr B Biomed Sci Appl; 2000 Apr; 740(2):159-68. PubMed ID: 10821401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates.
    Blaney SM; Takimoto C; Murry DJ; Kuttesch N; McCully C; Cole DE; Godwin K; Balis FM
    Cancer Chemother Pharmacol; 1998; 41(6):464-8. PubMed ID: 9554590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of topotecan.
    Herben VM; ten Bokkel Huinink WW; Beijnen JH
    Clin Pharmacokinet; 1996 Aug; 31(2):85-102. PubMed ID: 8853931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of irinotecan.
    Robert J; Rivory L
    Drugs Today (Barc); 1998 Sep; 34(9):777-803. PubMed ID: 14988754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.
    Drengler RL; Kuhn JG; Schaaf LJ; Rodriguez GI; Villalona-Calero MA; Hammond LA; Stephenson JA; Hodges S; Kraynak MA; Staton BA; Elfring GL; Locker PK; Miller LL; Von Hoff DD; Rothenberg ML
    J Clin Oncol; 1999 Feb; 17(2):685-96. PubMed ID: 10080615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.